Agenus Inc. (NASDAQ:AGEN) Shares Acquired by Fmr LLC

Fmr LLC increased its position in shares of Agenus Inc. (NASDAQ:AGEN) by 47.1% during the 3rd quarter, HoldingsChannel reports. The fund owned 85,301 shares of the biotechnology company’s stock after acquiring an additional 27,309 shares during the quarter. Fmr LLC’s holdings in Agenus were worth $467,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Point72 DIFC Ltd purchased a new position in Agenus during the second quarter worth about $51,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Agenus during the 2nd quarter worth approximately $106,000. Exchange Traded Concepts LLC raised its position in shares of Agenus by 52.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 27,543 shares of the biotechnology company’s stock valued at $151,000 after buying an additional 9,422 shares during the period. Blair William & Co. IL acquired a new position in Agenus in the second quarter valued at approximately $441,000. Finally, Squarepoint Ops LLC purchased a new position in Agenus in the second quarter worth approximately $614,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Stock Performance

Shares of AGEN stock opened at $2.71 on Thursday. The firm has a market cap of $63.57 million, a P/E ratio of -0.24 and a beta of 1.24. The firm’s 50 day moving average price is $3.70 and its 200-day moving average price is $7.19. Agenus Inc. has a one year low of $2.50 and a one year high of $19.69.

Analyst Ratings Changes

Separately, HC Wainwright restated a “neutral” rating on shares of Agenus in a research report on Thursday, December 5th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, Agenus has a consensus rating of “Hold” and a consensus target price of $10.00.

Agenus Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.